Jiangsu Hengrui Medicine Co., Ltd.
600276.SS
$-0.04
Change (1 day)
$7.89
Year High
$4.87
Year Low
Categories
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 840.85 M | -2,833,150,762 | 377.11 M | 6 B | 4.29 B |
| 2022 | 1.14 B | -1,884,690,678 | 540.27 M | 5.81 B | 4.24 B |
| 2021 | 943.51 M | -1,847,458,991 | 506.36 M | 5.38 B | 4.14 B |
| 2020 | 1.12 B | -1,261,372,157 | 540.37 M | 4.76 B | 3.84 B |
| 2019 | 744.89 M | -633,736,916 | 358.95 M | 3.78 B | 3.06 B |